A new breast cancer drug which extends women's lives by almost six months could be blocked from routine NHS access because it is too expensive, a health watchdog says.
Kadcyla, manufactured by Roche, can cost more than £90,000 per patient and is not effective enough to justify the price the NHS is being asked to pay, the National Institute for Health and Care Excellence (Nice) said.
The watchdog, which decides which new medicines are cost effective, said its guidance for the drug, also known as trastuzumab emtansine, was in draft form and is now up for public consultation.
If the recommendations are adopted, patients would have to apply to their local NHS and to the Cancer Drugs Fund (CDF) for the drug, a Nice spokeswoman said.
More top news
A man has been arrested and charged with assault with a rather unusual deadly weapon - a three foot alligator.
US dismisses Russian plans for Syrian ceasefire, saying the 1 March date creates a window in which Assad will try and crush moderate rebels.
Winter pressures faced by the NHS are "the new normal" for the rest of the year, according to a new report.